Consistent with the finding that SPOP‐mutated specimens acquire highest AR activity among different subtypes of PCa (Cancer Genome Atlas Research Network, 2015), SPOP‐mutated PCa cells are highly sensitive to treatment of androgen inhibitory agent abiraterone when SPOP mutation is co‐occurred with CHD1 deletion (Boysen et al, 2018), supporting the notion of oncogene addiction. The gene discussed is SPOP; the disease is posterior cortical atrophy.